Eli Lilly Signs Multi-Year Collaboration with Anima Biotech
Israel-based Anima will receive an upfront payment of $30 million and $14 million for research, but could potentially get as much as $1.05 billion in milestones
Lilach Baumer | 16:24 23.07.2018
Pharma multinational Eli Lilly and Company has signed a multi-year exclusive collaboration deal with Israel-based Anima Biotech Ltd., Anima announced Monday. As part of the agreement, Anima will receive an upfront payment of $30 million and $14 million in research funding, but could potentially get as much as $1.05 billion in milestones, according to the statement.
For daily updates, subscribe to our newsletter by clicking here.Founded in 2014 and headquartered in Tel Aviv, Anima has developed its patented technology in collaboration with the ribosome biochemistry lab at the University of Pennsylvania. The company uses big data-based analysis software to develop translation control therapeutics, a class of drugs that aim to control the synthesis of target proteins in the body and thus increase or decrease their production.